Vivoryon Therapeutics N.V. Expands Intellectual Property Portfolio with New U.S. Composition of Matter Patent Granted for Varoglutamstat
Globenewswire·2025-05-27 05:00
Vivoryon Therapeutics N.V. Expands Intellectual Property Portfolio with New U.S. Composition of Matter Patent Granted for Varoglutamstat Newly granted U.S. patent expected to provide exclusivity through 2044 with subsequent opportunity for patent term extensionNew U.S. patent granted after accelerated examination process covers the active polymorph of varoglutamstat, Vivoryon’s lead drug in development Additional patents for medical use and dosing regimens under examination for varoglutamstat and related st ...